Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Chemomab Therapeutics Ltd.CMMB · Entity 7653 | Director | May 24, 2022 | May 25, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Chemomab Therapeutics Ltd.
Report date May 24, 2022 · Filed May 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 1,433 |
Last balance in matching sequence
After 2022-05-24 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-05-24 · Purchase · Acquired 400 · Balance 1,400 F1: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. F2: Includes the previously reported 1,000 ADSs of the Company, as reported by Mr. Joel Maryles on Form 4 filed with the SEC on March 21, 2022. Row 2 · 2022-05-24 · Purchase · Acquired 33 · Balance 1,433 F1: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. F2: Includes the previously reported 1,000 ADSs of the Company, as reported by Mr. Joel Maryles on Form 4 filed with the SEC on March 21, 2022. |
| Option to Purchase American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $3.53 · Expires 2032-03-07 | Direct | 6,820 |
Reported balance
After 2022-03-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-07 · Grant · Acquired 6,820 · Balance 6,820 F3: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F4: These options vest and become exercisable in their entirety on March 16, 2023. F1: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. |
| Option to Purchase American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $27.26 · Expires 2031-04-19 | Direct | 11,884 |
Reported balance
After 2021-04-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-04-19 · Grant · Acquired 11,884 · Balance 11,884 F3: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F5: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. F1: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
F2: Includes the previously reported 1,000 ADSs of the Company, as reported by Mr. Joel Maryles on Form 4 filed with the SEC on March 21, 2022.
F3: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F4: These options vest and become exercisable in their entirety on March 16, 2023.
F5: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 24, 2022 Filed May 25, 2022 16:03 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 33 | $2.76 | $91.08 |
DisclosureSEC source: 0001178913-22-002173 · zk2227908.xml · nonDerivative · entry 2 Maryles Joel Michael · CIK 0001850990 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,433 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. F2 · balance_after: Includes the previously reported 1,000 ADSs of the Company, as reported by Mr. Joel Maryles on Form 4 filed with the SEC on March 21, 2022. Read SEC document |
| May 24, 2022 Filed May 25, 2022 16:03 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 400 | $2.89 | $1,156.00 |
DisclosureSEC source: 0001178913-22-002173 · zk2227908.xml · nonDerivative · entry 1 Maryles Joel Michael · CIK 0001850990 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. F2 · balance_after: Includes the previously reported 1,000 ADSs of the Company, as reported by Mr. Joel Maryles on Form 4 filed with the SEC on March 21, 2022. Read SEC document |
| March 18, 2022 Filed Mar 21, 2022 06:04 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 500 | $4.36 | $2,180.00 |
DisclosureSEC source: 0001178913-22-001181 · zk2227511.xml · nonDerivative · entry 2 Maryles Joel Michael · CIK 0001850990 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 18, 2022 Filed Mar 21, 2022 06:04 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 500 | $4.32 | $2,160.00 |
DisclosureSEC source: 0001178913-22-001181 · zk2227511.xml · nonDerivative · entry 1 Maryles Joel Michael · CIK 0001850990 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 16:01 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 6,820 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001178913-22-001018 · zk2227453.xml · derivative · entry 1 Maryles Joel Michael · CIK 0001850990 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,820 Underlying: American Depositary Shares · 6,820 shares Expires 2032-03-07 F1 · derivative.exercise_date: These options vest and become exercisable in their entirety on March 16, 2023. F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 07, 2022 Filed Mar 21, 2022 06:04 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 6,820 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001178913-22-001181 · zk2227511.xml · derivative · entry 3 Maryles Joel Michael · CIK 0001850990 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,820 Underlying: American Depositary Shares · 6,820 shares Expires 2032-03-07 F2 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F3 · derivative.exercise_date: These options vest and become exercisable in their entirety on March 16, 2023. F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 07, 2022 Filed May 25, 2022 16:03 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 6,820 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001178913-22-002173 · zk2227908.xml · derivative · entry 3 Maryles Joel Michael · CIK 0001850990 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,820 Underlying: American Depositary Shares · 6,820 shares Expires 2032-03-07 F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F4 · derivative.exercise_date: These options vest and become exercisable in their entirety on March 16, 2023. F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 17:11 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 11,884 | $0.00 Strike: $27.26 | $0.00 |
DisclosureSEC source: 0001104659-21-053230 · tm2113689-3_4.xml · derivative · entry 1 Maryles Joel Michael · CIK 0001850990 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,884 Underlying: American Depositary Shares · 11,884 shares Expires 2031-04-19 F1 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| April 19, 2021 Filed Mar 9, 2022 16:01 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 11,884 | $0.00 Strike: $27.26 | $0.00 |
DisclosureSEC source: 0001178913-22-001018 · zk2227453.xml · derivative · entry 2 Maryles Joel Michael · CIK 0001850990 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,884 Underlying: American Depositary Shares · 11,884 shares Expires 2031-04-19 F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F4 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| April 19, 2021 Filed Mar 21, 2022 06:04 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 11,884 | $0.00 Strike: $27.26 | $0.00 |
DisclosureSEC source: 0001178913-22-001181 · zk2227511.xml · derivative · entry 4 Maryles Joel Michael · CIK 0001850990 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,884 Underlying: American Depositary Shares · 11,884 shares Expires 2031-04-19 F2 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F4 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| April 19, 2021 Filed May 25, 2022 16:03 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 11,884 | $0.00 Strike: $27.26 | $0.00 |
DisclosureSEC source: 0001178913-22-002173 · zk2227908.xml · derivative · entry 4 Maryles Joel Michael · CIK 0001850990 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,884 Underlying: American Depositary Shares · 11,884 shares Expires 2031-04-19 F3 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F5 · derivative.exercise_date: These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.